Rivopharm was founded focusing its attention especially on the Swiss market, specializing in branded and generic pharmaceutical products.

Activities shift to mass production and Rivopharm supplies UNICEF and various International Humanitarian Organizations and Ministries of Health. Rivopharm invests in new equipment and technology to achieve quality, capability and efficiency.

Rivopharm expands its business in several countries of the former Soviet Union.

Refocus of activities to development and manufacture of generic products for European markets.

Significant investments are made to upgrade the production facilities to the latest cGMP standards. Rivopharm operates in a renovated plant, located in Manno, near Lugano.

Change of ownership of the company. Rivopharm is in partnership with many of Europe’s leading generics companies allowing for more important investments.

Increased production and packaging capacity by acquiring new equipment at all levels in the factory.

Large investment in modern technologies for Research and Development both in formulation and analytics.

Conclusion of several regulatory procedures at National and DCP level, including the first ever registration of Nicorandil tablets as generic product in some European countries.

First company to launch generic Nicorandil tablets in EU markets.

Successfully completed the registration dossier for Lacidipine tablets 2 mg, 4 mg and 6 mg. First ANDA filing scheduled for 2012.

Another exciting development concluded: Racecadotril capsules 100 mg; Opening of the representative office in London, UK for direct marketing of the products.

Historic achievement of passing FDA inspection with no 483’s.

First company to launch generic Racecadotril capsules.

Acquisition of Holsten Pharma, the new German affiliate of Rivopharm Group; In early 2016 Rivopharm SA obtained ANDA’s approval for 2 products.

Acquisition of Sanoswiss, the new affiliate of Rivopharm Group in Baltics. Launch of two generic products in US. Acquisition of a basket of 77 molecules from Teva

Start of direct marketing in Austria, Hungary and Poland